secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001193125-24-237227
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec reports positive interim data from BB-301 Phase 1b/2a: swallowing improvements in two OPMD subjects
--------------------------------------------------------------------------------

- Subject 1 at Day 270: 35% SSQ Total Score reduction, 33% VFSS TPR reduction for thin liquids.
- Subject 2 at Day 180: 89% SSQ Total Score reduction (score 82, clinically normal swallowing), 92% reduction in low-volume sequential swallows.
- No Significant Adverse Events observed with low-dose BB-301 (1.2e13 vg/subject).
- Third subject to be dosed this month; higher-dose cohorts enrollment expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524237227/0001193125-24-237227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524237227/d863953d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-237227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer